Scarica l'app Stockscreener
2.39
6.94%
0.155
Dopo l'orario di chiusura:
2.58
0.19
+7.95%
Ernexa Therapeutics Inc Borsa (ERNA) Ultime notizie
Ernexa appoints Robert Spiegel to board, targets IND filing By Investing.com - Investing.com Canada
Ernexa Therapeutics Says Board Addition Strengthens Oncology Strategy as ERNA-101 Advances Toward the Clinic - Quiver Quantitative
Ernexa Therapeutics Inc. (ERNA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ernexa completes safety studies for ERNA-101 cancer therapy By Investing.com - Investing.com Canada
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND - Yahoo Finance
An ovarian cancer study found Ernexa’s cell therapy combo cleared tumors; 100% of animals survived through follow-up. - Stock Titan
ERNA Stock Surged 60% Today – Here’s Why Retail Is Buzzing About Ernexa’s Ovarian Cancer Trial Results - Stocktwits
Ernexa (ERNA) director logs zero insider stake in new ownership report - Stock Titan
Ernexa Therapeutics Warrants (ERNAW) Tick Higher to $0.03 as Trading Range Stays Razor-ThinCounter Trend Trade - siam.in
Eterna Therapeutics appoints independent director Robert J. Spiegel - The Globe and Mail
Ernexa Therapeutics Inc. (ERNA) Q2 2026 Earnings: Narrower-Than-Feared Loss Fails to Lift Shares as Pipeline Costs PersistEBITDA Margin Trends - siam.in
Ernexa Therapeutics Announces Appointment of Robert J. Spiegel to Board of Directors - marketscreener.com
Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors - Yahoo Finance
Form 8K Ernexa Therapeutics Inc For: 16 September - Investing.com India
Form 8K Ernexa Therapeutics Inc For: 16 September By Investing.com - Investing.com South Africa
Eterna Therapeutics Updates Investors With New Corporate Materials - TipRanks
Ernexa names Robert J. Spiegel to its board - TradingView
Ernexa Therapeutics Reports Positive Preclinical ERNA-201 Data, Prioritizes ERNA-101 Oncology Program Toward IND Filing - Quiver Quantitative
Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing - GlobeNewswire
Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
Price to earnings forward of Ernexa Therapeutics Inc. – NASDAQ:ERNAW - TradingView
Enterprise value to EBIT forward of Ernexa Therapeutics Inc. – NASDAQ:ERNAW - TradingView
Enterprise value to revenue forward of Ernexa Therapeutics Inc. – NASDAQ:ERNAW - TradingView
Should I Buy ERNA? ERNA 2026 AnalysisIntellectia AI™ - Intellectia AI
Director takes 2026 cash pay in options at Ernexa (ERNA) - Stock Titan
Ernexa Therapeutics (ERNA) director granted options in place of cash fees - Stock Titan
Ernexa Therapeutics (ERNA) grants director 5,944-share option - Stock Titan
Ernexa Therapeutics Inc. (ERNA) grants CEO 118,848 options expiring 2036 - Stock Titan
Ernexa (NASDAQ: ERNA) pays director with $4.57 stock options - Stock Titan
Eterna Therapeutics Inc (NASDAQ: ERNA) Share Price, ERNA Stock News, ERNA Share Price & Updates - Kalkine
Ernexa Therapeutics : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Ernexa (NASDAQ: ERNA) director’s warrant set to lapse after Phase 1 data - Stock Titan
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference - Yahoo Finance
Ernexa (ERNA) Earnings Reading: Reported EPS Misses Expectations at the Close; Closing Move: The Market Price Advances 3.60%Free Cash Flow Trends - vinanet.vn
Ernexa (ERNA) Quarterly Results: Reported EPS Misses Expectations in the Current Update; Post-Report: The Share Price Adds 4.68% on the DayEBITDA Analysis - vinanet.vn
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know - qz.com
Ernexa Therapeutics Warrants (ERNAW) Hold at $0.05 as Price Action Remains FlatAccumulation Line - vinanet.vn
Ernexa Therapeutics (ERNA) Slips 2.2% to $4.17, Testing Key Support Amid Biotech PullbackCatalyst Driven Stocks - vinanet.vn
Ernexa Therapeutics (ERNA) Slips 0.7% to $4.27, Holds Above Key Support at $4.06Regression Channel - vinanet.vn
Ernexa Therapeutics Warrants (ERNAW) Surge 20% to $0.06 as Speculative Interest BuildsFibonacci Extension - vinanet.vn
Ernexa appoints David Polinsky to board ahead of IND filing By Investing.com - Investing.com Nigeria
Ernexa appoints David Polinsky to board ahead of IND filing - Investing.com
Ernexa Therapeutics Strengthens Board with Veteran Biotech - GlobeNewswire
Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage - The Manila Times
Ernexa Therapeutics Inc expected to post a loss of $3.84 a shareEarnings Preview - TradingView
Ernexa Therapeutics (NASDAQ: ERNA) details $9.5M loss and cash strategy - Stock Titan
Tranche Update on Ernexa Therapeutics Inc.'s Equity Buyback Plan announced on November 25, 2024. - marketscreener.com
Price to sales forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Price to earnings forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Enterprise value to EBIT forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Price to book forward of Ernexa Therapeutics Inc. – NASDAQ:ERNA - TradingView
Ernexa Therapeutics Inc. Revenue Breakdown – NASDAQ:ERNAW - TradingView
Ernexa Therapeutics Warrants (ERNAW) Hold Flat at $0.04 as Support and Resistance AlignDollar Neutral Pair - careplusvn.com
0.50%
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):